Research programme: dengue antibodies - Massachusetts Institute of Technology/Visterra

Drug Profile

Research programme: dengue antibodies - Massachusetts Institute of Technology/Visterra

Alternative Names: Monoclonal antibodies against dengue - Visterra; VIS-513

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke-NUS Graduate Medical School Singapore; Massachusetts Institute of Technology
  • Developer Massachusetts Institute of Technology; Visterra
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 18 Oct 2017 Visterra plans a phase I trial for VIS 513 for Dengue in 2018 (CTP#249894)
  • 05 Oct 2017 Research programme: dengue antibodies - Massachusetts Institute of Technology/Visterra is available for licensing as of 05 Oct 2017. www.visterrainc.com
  • 09 Sep 2015 VIS 513 licensed to Serum Institute of India in India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives and Sri Lanka
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top